skip to Main Content

Passionate about Science

World-class drug discovery expertise
and an unprecedented track record with 4 drugs on the market

Passionate about Science

World-class drug discovery expertise
and an unprecedented track record with 4 drugs on the market

WHYUS

We offer a unique blend of broad scientific expertise, global pharma heritage, and unprecedented success in bringing drug discovery projects from conception to the clinic. With a passionate, interdisciplinary and accomplished team, and capabilities ranging from target validation to clinical candidate nomination, we bring great science to your project.

LatestNews

A new year and a new publication

Oligomerization, Albumin Binding And Catabolism Of Therapeutic Peptides In The Subcutaneous Compartment: An Investigation On Lipidated GLP-1 Analogs

Oligomerization, albumin binding and catabolism of therapeutic peptides in the subcutaneous compartment: an investigation on lipidated GLP-1 analogs

Scientific Contributions
We are delighted to publish our first paper of 2022 in the Journal of Pharmaceutical and Biomedical Analysis (Elsevier). Here we leveraged our peptide #ADME toolbox to gain a better understanding of the interplay between oligomerization, albumin binding and catabolism of lipidated peptides in the subcutaneous compartment, using #GLP-1 analogs as model peptides.
read more

World AIDS Day

News
Today we remember and support #WorldAIDSDay. Medical research has seen amazing advances and milestones over the past few decades. Here at IRBM, we are proud to have played a major role in the discovery of Raltegravir (Isentress) while part of Merck & Co, for the treatment of #HIV-1 infection in combination with other antiretroviral agents.

Antios Therapeutics Announces Agreement with IRBM, INGM and OSR to Acquire Fourth-Generation HBV Capsid Assembly Modulators (CAMs)

News, Press Releases
Antios Therapeutics, Inc. (“Antios”), a clinical-stage biopharmaceutical company developing innovative therapies to treat and cure chronic hepatitis B virus (HBV), and IRBM, a drug discovery and early development research institute and global contract research organization, announced today they entered into an agreement for Antios to purchase the IP rights to a novel series of fourth-generation capsid assembly modulators (CAMs) being developed for the treatment of HBV.

A Series of Novel, Highly Potent, and Orally Bioavailable Next-Generation Tricyclic Peptide PCSK9 Inhibitors

Scientific Contributions
Following the first report in the Journal of Medicinal Chemistry in 2020, the IRBM peptide chemistry group is proud to announce a new publication on second generation, potent bi- and tricyclic PCSK9 inhibitor peptides in collaboration with the extraordinary drug discovery team at Merck & co.

NewsHighlights

The Power of NMR in Drug Discovery

The Power of NMR in Drug Discovery

Structural biology (SB) provides a critical drug discovery and development tool for accurately identifying and understanding the structure of a target. Alessandro Piai, PhD, Principal Research Scientist at IRBM, describes the company’s expertise in nuclear magnetic resonance (NMR) and how it can be leveraged to accelerate the identification of molecules for progression to the clinic.

Back To Top